Detail of "144494-65-5"

Reference

The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes

All Rights Reserved. The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes. Iliodromitis, Efstathios K.; Andreadou, Ioanna; Markantonis-Kyroudis, Sophia; Mademli, Kalliopi; Kyrzopoulos, Stamatis; Georgiadou, Panagiota; Kremastinos, Dimitrios Th. (2nd University Department of Cardiology, Medical School, Attikon General Hospital, University of Athens, Athens, Greece). Thrombosis Research, Volume Date 2007, 119(2), 167-174 (English) 2006 Elsevier B.V. CODEN: THBRAA. ISSN: 0049-3848. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Endothelial dysfunction and oxidative stress are believed to be central mechanisms in atherogenesis. We aimed to det. the effects of tirofiban on oxidative stress and neutrophil-endothelium interaction markers in patients with acute coronary syndromes (ACS). We measured malondialdehyde (MDA), interleukin-6 (IL-6) and sol. endothelial intercellular and vascular adhesion mols. (sICAM-1 and sVCAM-1) on admission, at 48 and 72 h and on 5th day of hospitalization in 34 patients (age 66.5±1.8 years) with ACS. Patients with recurrent angina, changes on the ECG and/or elevated troponin I received i.v. tirofiban for 48 h and the others received normal saline. Baseline concns. of all markers did not differ significantly and compared with placebo, tirofiban infusion markedly reduced MDA, IL-6, sICAM-1 and sVCAM-1 at 48 h (-31±6% vs. 542-78-9 and 144494-65-5 are cas registry numbers of chemicals which are used as reagents here. 84±49%, p = 0.007, -12±14% vs. 23±10%, p = 0.05, -20±6% vs. 36±25%, p = 0.04 and -10±5% vs. 6±5%, p = 0.02, resp.). Relative to baseline, significant redns. were obsd. for all 4 markers at 72 h and day 5 (p < 0.05). Tirofiban potentiates the decline in oxidative stress and may reverse abnormal endothelial activation in patients with ACS. This benefit seems to remain over the following 5 days. .

Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions

Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Goto, Shinya; Tamura, Noriko; Ishida, Hideyuki (Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan).Several substances are used for example 143653-53-6 and 144494-65-5 which are their cas registry numbers. Journal of the American College of Cardiology, 44(2), 316-323 (English) 2004 Elsevier Science Inc. CODEN: JACCDI. ISSN: 0735-1097. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 15 We examd. the lytic effects of anti-glycoprotein (GP) IIb/IIIa agents on platelet thrombi formed on the collagen surface under blood flow conditions. Anti-GP IIb/IIIa agents may influence platelet thrombi already formed. Blood samples were anticoagulated either by the specific antithrombin Argatroban (100 mM) or by unfractionated heparin (0.1 U/mL). After platelet thrombi were formed on a collagen surface following 6-min perfusion of whole blood obtained from eight adult donors contg. fluorescinated platelets at a wall shear rate of 1,500 s-1, addnl. blood samples from the same donors either contg. or not contg. anti-GP IIb/IIIa agents (abciximab, eptifibatide, or tirofiban) were perfused on these thrombi. The three-dimensional structures of the platelet thrombi were continuously obsd. by laser confocal microscopy equipped with a piezo-elec. motor control unit and recorded. The platelet thrombi started to dissolve after perfusion of blood contg. the anti-GP IIb/IIIa agents, whereas their growth resumed after subsequent perfusion of control blood. Only a single layer of platelets having heights of 3±1 mm, 3±2 mm, and 3±1 mm, resp., could be seen after 6-min perfusion of blood contg. abciximab, eptifibatide, and tirofiban, whereas the initial height of the platelet thrombi of 8±2 mm increased to 11±4 mm after subsequent perfusion of control blood (n = 8). The vol. of the platelet thrombi, which was 3,352±1,045 mm3 before starting the second perfusion, was reduced to 778±102 mm3, 812±122 mm3, and 856±144 mm3 after 6-min perfusion of blood contg. abciximab, eptifibatide, and tirofiban, resp. We have shown in this study that anti-GP IIb/IIIa agents possess the ability to dissolve platelet thrombi. .